Tara.Baron@ati.org2024-06-18T16:31:15-04:00
Next Gen Vaccinations: Phase 2b Clinical Trial Execution
Awards Made: 4
Total Amount Awarded: $551,167,891
tyler.bulin@ATI.ORG2024-06-19T12:43:43-04:00
Enabling Technology – Decentralized Clinical Trial – Home Focus
Member Organization: Allucent
Award Date: 05/14/2024
Award Amount: $25,514,420
Project Duration: 42 Months
tyler.bulin@ATI.ORG2024-07-19T14:29:14-04:00
Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine
Member Organization: Moderna
Award Date: 06/28/2024
Award Amount: $176,000,000
Project Duration: 60 Months
tyler.bulin@ATI.ORG2024-07-23T11:39:38-04:00
NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis: Modules 1 & 2
Member Organization: Fred Hutchinson Cancer Center
Award Date: 07/22/2024
Award Amount: Multiple
Project Duration: Multiple
tyler.bulin@ATI.ORG2024-07-23T15:02:23-04:00
Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus
Member Organization: Walgreen Co.
Award Date: 07/19/2024
Award Amount: $25,000,000
Project Duration: 22 Months
tyler.bulin@ATI.ORG2024-11-27T13:08:16-05:00
Biothreat Diagnostic Rapid Response
Awards Made: 2
Total Amount Awarded: $24,065,283
| Solicitation # | Solicitation Topic | Award Date | RRPV Member Awarded | Base Award | Focus Area |
|---|---|---|---|---|---|
| RPP-24-02-Retail | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 07/19/2024 | Walgreen Co. | $25,000,000 | Vaccines and Therapeutics |
| RPP-24-06-DxR2 | Biothreat Diagnostic Rapid Response | 09/30/2024 | InBios International, Inc. | $16,511,354 | Medical Technology |
| RPP-24-06-DxR2 | Biothreat Diagnostic Rapid Response | 11/26/2024 | OraSure Technologies, Inc. | $7,553,929 | Medical Technology |
| RPP-24-04-NGVxStats | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis: Module 2 | 07/22/2024 | Fred Hutchinson Cancer Center | $500,000 | Vaccines and Therapeutics |
| RPP-24-04-NGVxStats | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis: Module 1 | 07/22/2024 | Fred Hutchinson Cancer Center | $16,500,000 | Vaccines and Therapeutics |
| RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 06/28/2024 | ModernaTX, Inc. | $176,000,000 | Vaccines and Therapeutics |
| RPP-24-04-NGVx | Next Gen Vaccinations: Phase 2b Clinical Trial Execution | 06/13/2024 | Vaxart, Inc. | $452,884,477 | Vaccines and Therapeutics |
| RPP-24-04-NGVx | Next Gen Vaccinations: Phase 2b Clinical Trial Execution | 06/12/2024 | GeoVax, Inc. | $24,321,841 | Vaccines and Therapeutics |
| RPP-24-04-NGVx | Next Gen Vaccinations: Phase 2b Clinical Trial Execution | 06/04/2024 | CyanVac, LLC | $40,167,897 | Vaccines and Therapeutics |
| RPP-24-04-NGVx | Next Gen Vaccinations: Phase 2b Clinical Trial Execution | 06/03/2024 | CastleVax, Inc. | $33,793,676 | Vaccines and Therapeutics |
| RPP-24-02-HomeFocus | Enabling Technology – Decentralized Clinical Trial – Home Focus | 05/14/2024 | Allucent | $25,514,420 | Vaccines and Therapeutics |
